177 related articles for article (PubMed ID: 19111881)
1. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
Fotheringham S; Epping MT; Stimson L; Khan O; Wood V; Pezzella F; Bernards R; La Thangue NB
Cancer Cell; 2009 Jan; 15(1):57-66. PubMed ID: 19111881
[TBL] [Abstract][Full Text] [Related]
2. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
Khan O; Fotheringham S; Wood V; Stimson L; Zhang C; Pezzella F; Duvic M; Kerr DJ; La Thangue NB
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6532-7. PubMed ID: 20308564
[TBL] [Abstract][Full Text] [Related]
3. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
New M; Olzscha H; Liu G; Khan O; Stimson L; McGouran J; Kerr D; Coutts A; Kessler B; Middleton M; La Thangue NB
Cell Death Differ; 2013 Oct; 20(10):1306-16. PubMed ID: 23703321
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Borbone E; Berlingieri MT; De Bellis F; Nebbioso A; Chiappetta G; Mai A; Altucci L; Fusco A
Oncogene; 2010 Jan; 29(1):105-16. PubMed ID: 19802013
[TBL] [Abstract][Full Text] [Related]
5. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
6. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2.
Scognamiglio A; Nebbioso A; Manzo F; Valente S; Mai A; Altucci L
Biochim Biophys Acta; 2008 Oct; 1783(10):2030-8. PubMed ID: 18691615
[TBL] [Abstract][Full Text] [Related]
7. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.
Yu X; Li H; Zhu M; Hu P; Liu X; Qing Y; Wang X; Wang H; Wang Z; Xu J; Tan R; Guo Q; Hui H
J Invest Dermatol; 2020 Oct; 140(10):2009-2022.e4. PubMed ID: 32119867
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
12. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
13. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
16. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.
Zhou Q; Agoston AT; Atadja P; Nelson WG; Davidson NE
Mol Cancer Res; 2008 May; 6(5):873-83. PubMed ID: 18505931
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.
De Schepper S; Bruwiere H; Verhulst T; Steller U; Andries L; Wouters W; Janicot M; Arts J; Van Heusden J
J Pharmacol Exp Ther; 2003 Feb; 304(2):881-8. PubMed ID: 12538846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
